Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma-Reference-Cited by-同舟云学术

Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma

Published:2022-07 Issue: Volume:169 Page:32-41
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Pamporaki Christina^ORCID,Prodanov Tamara,Meuter Leah,Berends Annika M.A.,Bechmann Nicole^ORCID,Constantinescu Georgiana,Beuschlein Felix,Remde Hanna,Januszewicz Andrzej,Kerstens Michiel N.,Timmers Henri J.L.M.^ORCID,Taïeb David,Robledo Mercedes^ORCID,Lenders Jacques W.M.^ORCID,Pacak Karel,Eisenhofer Graeme^ORCID

Funder

National Institutes of Health

Deutsche Forschungsgemeinschaft

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Pheochromocytoma and extra-adrenal paraganglioma: updates;Tischler;Arch Pathol Lab Med,2008

2. Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting;Thompson;Hum Pathol,2021

3. Comprehensive molecular characterization of pheochromocytoma and paraganglioma;Fishbein;Cancer Cell,2017

4. Insights into mechanisms of pheochromocytomas and paragangliomas driven by known or new genetic drivers;Flores;Cancers,2021

5. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status;Eisenhofer;Eur J Cancer,2012

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The roles of genetic mutation and cytokines/chemokines in immune response and their association with uveal melanoma patient outcome;Heliyon;2024-09

2. Head and neck paragangliomas: recent advances in translational and clinical research and guidelines for patient care;Best Practice & Research Clinical Endocrinology & Metabolism;2024-09

3. Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/paraganglioma: long-term follow-up of 303 patients;Frontiers in Endocrinology;2024-08-21

4. International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents;Nature Reviews Endocrinology;2024-08-15

5. SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG;Best Practice & Research Clinical Endocrinology & Metabolism;2024-08